Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript

Core Insights - The conference call discusses preliminary results from the Phase I trial of ZW191, presented at the AACR-NCI-EORTC Conference in Boston [1][3] - The presentation includes a review of the design rationale and scientific principles behind ZW191's development [2] - Initial Phase I clinical data highlights will be summarized by Dr. Patricia LoRusso from Yale Cancer Center [3] Company Development - Zymeworks is focusing on the development path forward for ZW191 following the initial trial results [3] - The call will conclude with a Q&A session involving Dr. LoRusso and the Senior Vice President of Clinical Development [3]